|
1
|
Van Cutsem E, Rivera F, Berry S, et al:
First BEAT investigators: Safety and efficacy of first-line
bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in
metastatic colorectal cancer: the BEAT study. Ann Oncol.
20:1842–1847. 2009.PubMed/NCBI
|
|
2
|
Van Cutsem E, Köhne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
3
|
Tol J, Koopman M, Cats A, et al:
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kinoshita M, Kodera Y, Hibi K, et al: Gene
expression profile of 5-fluorouracil metabolic enzymes in primary
colorectal cancer: potential as predictive parameters for response
to fluorouracil-based chemotherapy. Anticancer Res. 27:851–856.
2007.
|
|
6
|
Okumura K, Shiomi H, Mekata E, et al:
Correlation between chemosensitivity and mRNA expression level of
5-fluorouracil-related metabolic enzymes during liver metastasis of
colorectal cancer. Oncol Rep. 15:875–882. 2006.
|
|
7
|
Aschele C, Debernardis D, Casazza S, et
al: Immunohistochemical quantitation of thymidylate synthase
expression in colorectal cancer metastases predicts for clinical
outcome to fluorouracil-based chemotherapy. J Clin Oncol.
17:1760–1770. 1999.
|
|
8
|
Soong R, Shah N, Salto-Tellez M, et al:
Prognostic significance of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase protein expression in
colorectal cancer patients treated with or without
5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.
View Article : Google Scholar
|
|
9
|
Bruey JM, Ducasse C, Bonniaud P, et al:
Hsp27 negatively regulates cell death by interacting with
cytochrome c. Nat Cell Biol. 2:645–652. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mehlen P, Schulze-Osthoff K and Arrigo AP:
Small stress proteins as novel regulators of apoptosis. Heat shock
protein 27 blocks Fas/APO-1- and staurosporine-induced cell death.
J Biol Chem. 271:16510–16514. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andrieu C, Taieb D, Baylot V, et al: Heat
shock protein 27 confers resistance to androgen ablation and
chemotherapy in prostate cancer cells through eIF4E. Oncogene.
29:1883–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarto C, Valsecchi C, Magni F, et al:
Expression of heat shock protein 27 in human renal cell carcinoma.
Proteomics. 4:2252–2260. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song TF, Zhang ZF, Liu L, Yang T, Jiang J
and Li P: Small interfering RNA-mediated silencing of heat shock
protein 27 (HSP27) increases chemosensitivity to paclitaxel by
increasing production of reactive oxygen species in human ovarian
cancer cells (HO8910). J Int Med Res. 37:1375–1388. 2009.
View Article : Google Scholar
|
|
14
|
Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO,
Welch WJ and McGuire WL: Response of human breast cancer cells to
heat shock and chemotherapeutic drugs. Cancer Res. 52:3648–3654.
1992.PubMed/NCBI
|
|
15
|
Vargas-Roig LM, Gago FE, Tello O, Aznar JC
and Ciocca DR: Heat shock protein expression and drug resistance in
breast cancer patients treated with induction chemotherapy. Int J
Cancer. 79:468–475. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garrido C, Mehlen P, Fromentin A, et al:
Inconstant association between 27-kDa heat-shock protein (Hsp27)
content and doxorubicin resistance in human colon cancer cells. The
doxorubicin-protecting effect of Hsp27. Eur J Biochem. 237:653–659.
1996. View Article : Google Scholar
|
|
17
|
Choi DH, Ha JS, Lee WH, et al: Heat shock
protein 27 is associated with irinotecan resistance in human
colorectal cancer cells. FEBS Lett. 581:1649–1656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tweedle EM, Khattak I, Ang CW, et al: Low
molecular weight heat shock protein HSP27 is a prognostic indicator
in rectal cancer but not colon cancer. Gut. 59:1501–1510. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Z, Zhi J, Peng X, Zhong X and Xu A:
Clinical significance of HSP27 expression in colorectal cancer. Mol
Med Rep. 3:953–958. 2010.PubMed/NCBI
|
|
20
|
Wang F, Zhang P, Shi C, Yang Y and Qin H:
Immunohistochemical detection of HSP27 and hnRNP K as prognostic
and predictive biomarkers for colorectal cancer. Med Oncol. Aug
23–2011.(Epub ahead of print).
|
|
21
|
Tsuruta M, Nishibori H, Hasegawa H, et al:
Heat shock protein 27, a novel regulator of 5-fluorouracil
resistance in colon cancer. Oncol Rep. 20:1165–1172.
2008.PubMed/NCBI
|
|
22
|
Kamada M, So A, Muramaki M, Rocchi P,
Beraldi E and Gleave M: Hsp27 knockdown using nucleotide-based
therapies inhibit tumor growth and enhance chemotherapy in human
bladder cancer cells. Mol Cancer Ther. 6:299–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rocchi P, So A, Kojima S, et al: Heat
shock protein 27 increases after androgen ablation and plays a
cytoprotective role in hormone-refractory prostate cancer. Cancer
Res. 64:6595–6602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rocchi P, Beraldi E, Ettinger S, et al:
Increased Hsp27 after androgen ablation facilitates
androgen-independent progression in prostate cancer via signal
transducers and activators of transcription 3-mediated suppression
of apoptosis. Cancer Res. 65:11083–11093. 2005. View Article : Google Scholar
|
|
25
|
Sun Y, Tang XM, Half E, Kuo MT and
Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic
susceptibility by inhibiting the cytochrome c-dependent apoptotic
pathway in human colon cancer cells. Cancer Res. 62:6323–6328.
2002.PubMed/NCBI
|
|
26
|
Kluck RM, Bossy-Wetzel E, Green DR and
Newmeyer DD: The release of cytochrome c from mitochondria: a
primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li P, Nijhawan D, Budihardjo I, et al:
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9
complex initiates an apoptotic protease cascade. Cell. 91:479–489.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Concannon CG, Orrenius S and Samali A:
Hsp27 inhibits cytochrome c-mediated caspase activation by
sequestering both pro-caspase-3 and cytochrome c. Gene Expr.
9:195–201. 2001.PubMed/NCBI
|
